The other 3 individuals with a relapse never met the criteria for B-cell depletion. Raises in ANCA titer did not predict relapses in either treatment group . There have been four deaths, two in each group .). 23, P<0.001). There is no significant difference between your treatment groups in the quantity or rate of attacks of grade 3 or more.03); not all of these patients needed hospitalization or intravenous antibiotic therapy. Serum degrees of IgG, IgA, and IgM, as well as the true number of sufferers with low levels of these immunoglobulins, did not differ between the two groupings at baseline significantly, 6 months, or 1.22 biomarkers offering a more accurate screening for prostate Researchers in the University of Michigan Comprehensive Cancer Center have identified a panel of 22 biomarkers that together provide a more accurate screening for prostate malignancy than the current prostate specific antigen, or PSA, test. The study appears in today’s issue of the brand new England Journal of Medication. Researchers looked at blood samples taken from 331 prostate cancers patients prior to surgery, and from 159 control males without history of cancer. They began by screening the samples against a library of 2,300 bacteriophage, organisms that express proteins on their surface, and were able to narrow the field to the 22 biomarkers that a lot of frequently pinpointed the cancerous blood samples.